Overview
Registration
Agenda
Faculty
View Archive

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation, TG Therapeutics, Inc., and Verastem, Inc.

The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets Into Clinical Practice

The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets Into Clinical Practice


Friday, December 4, 2020

Live, Interactive Virtual Webcast!

11:00 AM – 1:30 PM PST

Overview

Dysregulation of phosphatidylinositol 3-kinase (PI3K) activity is a common feature in human cancer cells. The activated PI3K pathway, including downstream signaling via AKT and mTOR, imparts competitive growth and survival, increased metastatic stability, and resistance to conventional therapy for malignant tumors. Targets of PI3K, an isoform of PI3K that is essential for B-cell survival, are of considerable interest in B-cell malignancies. Over the past several years, 3 PI3K inhibitors have been approved for the treatment of patients with hematologic malignancies, and now a slew of novel PI3K inhibitors at various stages of development are under investigation as well. Clinicians will need to evaluate the latest clinical data on the efficacy and safety of this class of agents to understand which of their patients will most likely benefit from this treatment strategy.

The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets Into Clinical Practice is a CME-certified live webcast to be held on Friday, December 4, 2020. In this educational program, renowned experts in hematologic malignancies will review the rationale for PI3K inhibitors in the treatment of chronic lymphocytic leukemia and lymphoma, as well as assess the recent clinical trial available. The experts will provide insights on the identification of patients likely to achieve greatest clinical benefit with PI3K inhibitors, the practical implications of utilizing PI3K inhibitors in the clinic, and the impact of PI3K inhibitors on patients with hematologic malignancies.

Benefits of Attending

  • Get the latest information on recent clinical data with PI3K inhibitors in hematologic malignancies
  • Hear experts discuss the impact of PI3K inhibitors in patients with hematologic malignancies
  • Learn about patient factors to consider when selecting PI3K inhibitor treatment

Acknowledgment of Commercial Support

This activity is supported by educational grants from Incyte Corporation, TG Therapeutics, Inc., and Verastem, Inc.

Target Audience

This activity is directed toward the ASH audience—primarily hematologists, medical oncologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Examine the rationale supporting the use of PI3K inhibitors in the treatment of patients with hematologic malignancies in the relapsed and refractory settings
  • Recognize the role of PI3K inhibitors in the treatment of hematologic malignancies in the relapsed and refractory settings
  • Review emerging data as well as planned and ongoing trials focused on evaluating current and emerging PI3K inhibitors in the treatment of hematologic malignancies
  • Create individualized plans to educate patients and manage treatment-related toxicities in patients being treated with PI3K inhibitors

Program Chair

Javier Pinilla-Ibarz, MD, PhD
Javier Pinilla-Ibarz, MD, PhD
Senior Member
Head of Lymphoma Section and Director of Immunotherapy
Malignant Hematology Department
H. Lee Moffitt Cancer Center
Professor, Department of Oncologic Sciences
University of South Florida
Tampa, Florida

Registration

2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
 
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.



Register

You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information


Registration Information


Professional Information


Specialties*

Submit
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By